Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 8, 2011, Pages 1836-1840

  Niitsu, Tomihisa ^a   Shirayama, Yukihiko ^a,b   Matsuzawa, Daisuke ^a   Hasegawa, Tadashi ^a   Kanahara, Nobuhisa ^a   Hashimoto, Tasuku ^a   Shiraishi, Tetsuya ^a   Shiina, Akihiro ^a   Fukami, Goro ^a   Fujisaki, Mihisa ^a   Watanabe, Hiroyuki ^a   Nakazato, Michiko ^a   Asano, Makoto ^c   Kimura, Sho ^d   Hashimoto, Kenji ^e   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c Chiba Psychiatric Medical Center   (Japan)

^d Kimura Hospital   (Japan)

^e CHIBA UNIVERSITY   (Japan)

Author keywords

BDNF; Cognitive impairment; Negative symptom; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRONANSERINE; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ANHEDONIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE DURATION; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOMS SCALE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; PREFRONTAL CORTEX; PROTEIN BLOOD LEVEL; PSYCHOLOGIC TEST; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; STROOP TEST; VERBAL MEMORY; WECHSLER INTELLIGENCE SCALE; WORKING MEMORY;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 82455192417     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.09.004     Document Type: Article

References (54)

1. Adcock R.A., Dale C., Fisher M., Aldebot S., Genevsky A., Simpson G.V., et al. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophrenia Bull 2009, 35:1132-1141.
2. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982, 39:784-788.
3. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005, 10:345-352.
4. Bow-Thomas C.C., Velligan D.I., Miller A.L., Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res 1999, 86:131-142.
5. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007, 91:1-5.
6. Carlino D., Leone E., Di Cola F., Baj G., Marin R., Dinelli G., et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 2011, 45:273-279.
7. Carter C.S., Mintun M., Cohen J.D. Interference and facilitation effects during selective attention: an H215O PET study of Stroop task performance. Neuroimage 1995, 2:264-272.
8. Chan M.W., Yip J.T., Lee T.M. Differential impairment on measures of attention in patients with paranoid and nonparanoid schizophrenia. J Psychiatr Res 2004, 38:145-152.
9. Chen C.C., Huang T.L. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res 2011, [Epub ahead of print].
10. Czubak A., Nowakowska E., Kus K., Burda K., Metelska J., Baer-Dubowska W., et al. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 2009, 61:1017-1023.
11. Dickerson F., Boronow J.J., Ringel N., Parente F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr Res 1999, 37:13-20.
12. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000, 14:1-21.
13. Erhart S.M., Marder S.R., Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 2006, 32:234-237.
14. Fumagalli F., Calabrese F., Luoni A., Bolis F., Racagni G., Riva M.A. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 2011, 1-12.
15. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007, 420:45-48.
16. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
17. Green M.F., Marshall B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am J Psychiatry 1997, 154:799-804.
18. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004, 56:301-307.
19. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2010, Epub ahead of print.
20. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007, 41:31-35.
21. Guimaraes L.R., Jacka F.N., Gama C.S., Berk M., Leitao-Azevedo C.L., Belmonte de Abreu M.G. Serum levels of brain-derived neurotrophic factor in schizophrenia on a hypocaloric diet. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1595-1598.
22. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr Bull 2006, 32:250-258.
23. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86:138-146.
24. Huang T.L., Lee C.T. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 2006, 40:664-668.
25. Igarashi K., Oguni H., Osawa M., Awaya Y., Kato M., Mimura M., et al. Wisconsin card sorting test in children with temporal lobe epilepsy. Brain Dev 2002, 24:174-178.
26. Inada T., Yagi G., Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 2002, 57:227-238.
27. Ingvar D.H., Franzen G. Distribution of cerebral activity in chronic schizophrenia. Lancet 1974, 2:1484-1486.
28. Jockers-Scherubl M.C., Danker-Hopfe H., Mahlberg R., Selig F., Rentzsch J., Schurer F., et al. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 2004, 371:79-83.
29. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64:633-647.
30. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214-219.
31. Lee A.H., Lange C., Ricken R., Hellweg R., Lang U.E. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol 2011, 31:334-336.
32. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005, 162:495-506.
33. Misawa G., Kobayashi S., Fujita K., Maekawa H., Dairoku H. Japanese Wechsler Adult Intelligence Scale-Revised short forms 1993, Nihon Bunka Kagakusha Co. Ltd., Tokyo, (in Japanese).
34. Nakamura H., Nakanishi M., Furukawa T.A., Hamanaka T., Tokudome S. Validity of brief intelligence tests for patients with Alzheimer's disease. Psychiatry Clin Neurosci 2000, 54:435-439.
35. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H. BDNF function and intracellular signaling in neurons. Histol Histopathol 2010, 25:237-258.
36. Oltmanns T.F., Neale J.M. Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty?. J Abnorm Psychol 1975, 84:205-209.
37. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
38. Pirildar S., Gonul A.S., Taneli F., Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:709-713.
39. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin Neurosci 2010, 12:383-392.
40. Reis H.J., Nicolato R., Barbosa I.G., Teixeira do Prado P.H., Romano-Silva M.A., Teixeira A.L. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett 2008, 439:157-159.
41. Reitan R.M., Wolfson D. The Halstead Reitan Neuropsychological Test Battery: theory and clinical interpretation 1993, Neuropsychology Press.
42. Rizos E.N., Michalopoulou P.G., Siafakas N., Stefanis N., Douzenis A., Rontos I., et al. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology 2010, 62:87-90.
43. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2010, 11:251-255.
44. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1308-1311.
45. Shad M.U., Tamminga C.A., Cullum M., Haas G.L., Keshavan M.S. Insight and frontal cortical function in schizophrenia: a review. Schizophr Res 2006, 86:54-70.
46. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003, 351:111-114.
47. Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007, 115:4-11.
48. Sumiyoshi C., Sumiyoshi T., Nohara S., Yamashita I., Matsui M., Kurachi M., et al. Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. Schizophr Res 2005, 74:91-100.
49. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005, 382:27-32.
50. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002, 110:249-257.
51. Vinogradov S., Fisher M., Holland C., Shelly W., Wolkowitz O., Mellon S.H. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol Psychiatry 2009, 66:549-553.
52. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci 1988, 11:367-370.
53. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667.
54. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Xu Q., et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 2007, 41:997-1004.